2.2. Study Participants: Inclusion and Non-Inclusion Criteria
SAH, psychotic history, dementia, psychosis, neurological or psychiatric, cognitive or motor skills;Patient, endovascular occlusion
RUPTURED CEREBRAL ANEURYSM, RUPTURED ANEURYSM, INTRAVENTRICULAR HEMORRHAGE
We identified eligible patients through standard clinical practice, and all patients provided consent before enrollment. The inclusion criteria for the TRIVASOSTIM study were as follows:Patient had to be aged between 18 and 75 years;Patient was admitted within 48 h after the onset of SAH;Patient had a ruptured cerebral aneurysm confirmed by computerized tomography angiography (CTA) or cerebral angiography;Patient had no progressive psychosis or serious psychotic history requiring hospitalization;Patient had no progressive cancerous pathology;Patient was a candidate for management of his/her ruptured aneurysm, either by endovascular occlusion or microsurgical exclusion;Patient had a grade between I and IV according to the classification of the World Federation of Neurosurgical Societies (WFNS);Patient or a trusted person was able to understand and accept the constraints of the study (patient or trusted person, depending on the vigilance and cooperation of the patient);Patient was affiliated with a health insurance plan;Patient or a trusted person provided written consent to the study after receiving clear information.Patients meeting one or several of the following criteria were not included in the study:Patient was receiving reinforced protection (i.e., minors, pregnant or breast-feeding women, persons deprived of their liberty by a legal or administrative authority, persons staying in a health or social institution, and adults under legal protection);Patient had proven dementia or a neurological or psychiatric history that might affect their cognitive or motor skills;Patient had a clinical severity of grade V according to the WFNS classification (very high risk of mortality);Patient had an intracerebral or intraventricular hemorrhage, without a subarachnoid component;Patient had SAH without evidence of an aneurysm;Patient had an unruptured brain aneurysm;Patient had a contraindication for the placement of a TENS device, including patients with an electronic pacemaker;Patient had dermatological problems in the stimulation area that contraindicated the use of TENS patches.